Drugs and vaccines
The supply of medicine in the world has now become a lucrative and prosperous market that if every country can not stand on its own two feet in this area, the cost of this reliance on others, will probably bend its back! The expert force in this field can increase or decrease the borders of a country’s exports and imports and support the country even in financial crises by valuing it with a practical medicine. Certainly, the role of any society is to find talented and interested people in this field, so in Iran, we see the attraction of these people in every superior university and we are witnessing the result now.
The position of the Islamic Republic of Iran in the world
At present, Iran is among the top 7 countries in the world in the field of pharmacy, and some believe that the evidence shows that our country is the emerging power of the pharmaceutical industry in the world.
Alireza Yektadoust, a member of the board of directors of Darupakhsh Factories Company, states that pharmacy is one of the largest industries in the world with an annual growth of 3 to 6 percent; The revenue of the world’s pharmaceutical industry has increased from $ 800 billion in 2009 to $ 1,250 billion in 2019, and is even projected to reach $ 1,500 billion in 2023.
In Iran, the per capita drug is about $ 75, which is due to the relative low per capita cost of drugs in Iran is that we mainly use general drugs and in general, the price of drugs in Iran is lower than in other countries in the region.
One-fifth of the total R&D costs of the world’s businesses are in the pharmaceutical industry, with 15 percent of the industry’s sales revenue being reinvested in R&D. Innovation and marketing are the two main challenges of the pharmaceutical industry, and companies that are capable in these two areas will be more successful.
We are one of the emerging powers in the world pharmaceutical industry
Iran is one of the emerging powers in the world pharmaceutical industry. The value of our country’s drug production market has reached 35,000 billion tomans this year, if this industry has grown by an average of 28 to 30 percent annually in the last 10 years, and this has made Iran shine in this field.
In the discussion of self-sufficiency in the production of drugs, Iran has acknowledged that the domestic production rate has reached 97%. Mohammad Reza Shanesaz, head of the Food and Drug Administration, says: “It is not a small honor at all that we produce 97% of the medicine ourselves in Iran.” Pharmacists in the country have a special place in the growth and promotion of the scientific rank of the country, and in the dimension of production, the position of the country’s pharmacy has a prominent and brilliant role in paying and implementing resistance economic policies.
“Pharmacists are among the first to take action against any virus or disease in the world, such as the coronavirus, which has driven all pharmacists to produce vaccines, and this shows a sense of responsibility and scientific ability that They have been working for it for years.
America’s big lie about not banning food and medicine
The head of the Food and Drug Administration said: “Although it is said that drugs and food are an exception in the sanctions, but this is a big lie and it is planned that the supply of medicine and medical equipment to the Iranian people as a priority of the enemy, but capability Our country’s pharmacists prevented this sinister goal.
“Some of our major problems in supplying medicine and medical equipment are seen as money transfers, but the issues are beyond that,” Shansaz said, noting that the world is witnessing pressure from pharmaceutical companies and medical equipment to work with Iran. So that some pharmaceutical companies that have been working with Iran for years and continued to work with Iran in the previous period of sanctions are under pressure. Some companies have been working with Iran for more than five decades in the field of raw material supply, but now they supply our raw materials with great delay.
“If we had 50 to 60 percent production in the field of pharmaceutical raw materials, we hope to increase production to 85 to 90 percent in the short term, which is a very big event,” he said.
He said: “People who are not very familiar with the science of pharmacy, always declared a subject as a weakness and said how do you do pharmacy when raw materials come from abroad?” We attribute this to their unfamiliarity with the science of pharmacy.
What do certain patients do in the face of sanctions?
Butterfly patients were among the special patients whose lives were directly affected by the sanctions. The disease, which is caused by a genetic mutation, will plague the patient for the rest of his life.
Patients suffer from a lot of pain because their skin peels off every day and they have to apply an ointment called a dressing to heal these skin wounds that lead to superficial and deep wounds in the body. Due to the special conditions of eBay patients, these dressings must be changed and used day by day, but on the other hand, they are very expensive. Only a few companies outside Iran are producing this type of dressing, and despite US sanctions, 750 Iranians suffering from the disease are in trouble. A few months ago, a butterfly patient named Ava, who was only two years old, died due to a severe infection and lack of the necessary dressing.
Even nuclear drugs, which are required to scan for cancer, have been sanctioned by the United States because of their links to Iran’s nuclear energy industry, and have put the lives of many Iranians at risk.
Radiopharmaceutical raw materials are like ice. If they are not delivered on time, they will melt and rot. The preparation of nuclear drugs is also very complicated, because these substances are usually very short-lived and must be transported very quickly.
However, in this crisis, Iran, as always, is trying to circumvent and solve problems, and these sanctions have become a bridge for its growth in the pharmaceutical industry. Despite the high cost of 3% of the drug that Iran is not currently able to produce, domestic specialists still make similar drugs at a much lower cost than the foreign sample and take steps to develop and even export drugs worldwide.
The current position of the pharmaceutical industry
Development of the country’s pharmaceutical industry and achieving a positive balance in the country’s pharmaceutical industry so that the required currency of the pharmaceutical industry is provided through drug exports and the ultimate goal of the pharmaceutical industry while maintaining the domestic market is to export and exchange currency for the country. Export is the engine of production and drives production. Today, 55% of pharmaceutical raw materials are produced by high-tech knowledge-based companies (single) in the country, and more than 95% of packaging materials and supplies are provided within the production and needs of pharmaceutical companies. At present, 97% of the drugs required by the country are produced and produced domestically and about 3% are imported as manufactured drugs.
At present, 110 pharmaceutical factories are active in the country and about 30 pharmaceutical companies produce their drugs on a contract basis in those factories, along with 70 pharmaceutical raw material companies and 56 drug distribution companies along with 13,000 pharmacies in the supply of case drugs. The needs of our compatriots are working and today, despite the sanctions, we have 600 drug molecules, 2,000 generic drug doses and about 11,000 branded drug doses in Iran. To produce medicine in the country.
Nanocurcumin is the first herbal nanomedicine in Iran, the active ingredient of which is derived from turmeric, produced to reduce the growth and proliferation of cancer cells.
International research has shown the effectiveness of curcumin in the treatment of cancer, but no product has been offered internationally yet.
But Iranian researchers at Danesh-Bonyan Elixir NanoSina have marketed the formula of this drug along with Sina Doxosum, which is an advanced nanomedicine for the treatment of breast cancer.
Hessa is one of the Iranian drugs that has no foreign counterpart and is used to reduce pain and increase appetite in cancer patients and also to strengthen the immune system.
The Iranian drug Imod, which is produced in the country to strengthen the immune system of people living with AIDS, is one of the exclusive Iranian drugs that has reached the world record. The drug is distributed free of charge to this group of patients at different times.
Radiopharmaceuticals produced in Iran since the use of nuclear energy also made Iran one of the few countries capable of producing these drugs.
Although domestic research has shown the effectiveness and safety of these drugs, but unfortunately at the international level, no significant research has been done on them and these drugs have not been registered, so they are prescribed and sold only in Iran.
Iranian pharmacy after the embargo
Although the officials of the Ministry of Health have repeatedly emphasized in their speeches that drugs are not sanctioned, the problems of currency transfer and reopening of the LC for importing drugs have always been one of the concerns of this ministry during the sanctions.
During this period, shortages of raw materials for medicine also led to the closure of some production lines. For example, the production of growth hormone in Samen Pharmacy in Mashhad was stopped by the Australian company refusing to deliver raw materials.
It is certain that after the lifting of sanctions and the facilitation of currency transfers, the country’s pharmaceutical situation will be accompanied by great fear and hope.
Despite the promise of the Ministry of Health not to allocate surplus currency for drug imports and to continue to support domestic industries, the lifting of sanctions could reduce the domestic pharmaceutical industry’s market share, which rose to 67% in 1993.
However, lowering the price of imported drugs, facilitating the import of raw materials from developed countries and increasing the quality of Iranian drugs can be considered as positive effects of the lifting of sanctions on the Iranian pharmaceutical industry.